Forthcoming Issue

Peer review articles planned or manuscripts submitted for peer review approval and publication in the forthcoming issues.

Online First

Online First articles have been peer reviewed, accepted for publication and published online; they have not yet been assigned to a journal issue. When an article is published in a journal issue with the assigned page number, it will be removed from the ‘Forthcoming Issue’ page.

Online First articles are copyedited by the science editors and the editorial production team; typeset, proofread and approved by the author(s) before publication. We aim to post each article within six weeks of acceptance and within two weeks after final proofreading approval by the author. Online First articles are in searchable full text, with the initial online publication date included in the final print version.

Articles appearing on the ‘Forthcoming Issue’ page are in the order of the Journal Editorial Sections.  You may also view the abstract by clicking on the article link.

Subscribe now to the print or PDF copy of GaBI Journal to view full information of the following manuscripts*.

Editor’s Letter

What to look forward to in GaBI Journal, 2022, Issue 2 / Professor Philip D Walson, MD, USA


Substitution and interchangeability: time for a conversation? / Chad Rieger, MBA; Lisa Hall, PhD; David Lim, DPH, Australia

Original Research

On statistical evaluation for interchangeability of biosimilar products / Yuqi Li, BS Pharm; Professor Shein-Chung Chow, PhD, USA

A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy / Federico J Piñeiro, Pharm, MPH, Argentina; Fernández Argüelles Rogelio Alberto, Pharm, PhD, Mexico

US prescribers’ attitudes and perceptions about biosimilars / Ralph McKibbin, MD; Michael S Reilly, Esq

Social trust, economic incentives, and regional variation in the adoption of biosimilars in Italy and Germany / Professor James C Robinson, PhD, MPH

Pharmacokinetic bioequivalence of sitagliptin phosphate tablet formulations: a randomized, open-label, crossover study in healthy volunteers / Chuei Wuei Leong, PhD; Elton Sagim, BBiomedSc; Kar Ming Yee, BPharm; Muhammad Shalhadi Saharuddin, BSc; Nik Mohd Zulhakimi Nik Abdullah, BSc; Noramirah Farhanah Saberi, BSc; Rajavikraman Boopathy0, DipSc; Shahnun Ahmad, MBBS; Atiqah Amran1, BSc; Raman Batheja, PhD; Rajan Sharma, MBBS; Kiran Kumar Vuppalavanchu, MPharm

Review Articles

Manufacture and regulation of cell, tissue and gene therapy products: global perspectives, challenges and next steps / Adjunct Associate Professor Sia Chong Hock, BSc (Pharm), MSc, Associate Professor Chan Lai Wah, BSc (Pharm) (Hon), PhD, Christine Koh, BSc (Pharm) (Hon), PhD, Singapore

Development of Ph. Eur. standards for therapeutic monoclonal antibodies: infliximab case study / M Buda, PhD

Meeting Report

Key factors for successful uptake of biosimilars: Europe and the US / Michael S Reilly, Esq; Professor Philip J Schneider, MS, FASHP, FASPEN, FFIP, USA


Regulatory pathway for approval of ‘biosimilars’ in Iran / Jalal Naeli, MD, Iran

Sponsored Article

Front-loading biosimilar development with analytical characterization

Click here for more details on the educational series.

Contact us for an updated list of editorial topics in forthcoming issues.

*Editorial content may differ from final version of manuscript published in print.

Source URL:

Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048